August 18, 2014
Browse or download the PDF of our latest issue.

Get weekly news in your inbox!

Vanier scholar aims for hepatitis breakthrough

Billy-Ray Belcourt
Gateway Staff
Oct 02, 2013

In 1982, the first ever vaccine was created to prevent a pervasive form of cancer caused by the hepatitis B virus. But despite this medical breakthrough, approximately 600,000 people die from hepatitis B-related health complications each year.

This troubling statistic had U of A student Connie Le determined to put this medical phenomenon under the microscope — a research pursuit made possible by her selection as a Vanier Scholar, a designation that will provide her project with $150,000 over three years.

Once she completes the first two years of her medical degree, Le will diligently pursue her research, which will attempt to develop a short-term therapy to treat those infected with hepatitis B. She also hopes to provide relief for the 240 million people infected with the virus by finding an effective cure for the disease.

“Essentially the idea is to still administer the current therapy for hepatitis B to patients, but in combination with what my research will hopefully come to fruition with — something else that would also attack that DNA portion,” she said.

“If that’s the case, that would essentially be a cure for hepatitis B.”

According to the World Health Organization, hepatitis B is most commonly contracted through sexual transmission, contaminated needles and from mother to child during birth. Although hepatitis B is common throughout the world, especially in sub-Sahara Africa and East Asia, Le said it hasn’t been given the attention it deserves. The current long-term therapy is both expensive and physically uncomfortable, restricting access to those from low-income backgrounds, she explained.

“It’s quite prevalent worldwide. It’s one of those diseases that hasn’t gotten quite as much publicity as some of the other ones,” she said.

“On top of that, a lot of individuals have trouble going on the therapy. It’s not an incredibly comfortable therapy ... (and) it can be quite expensive. Being able to shorten that therapy and provide something to end the need for continued therapy could help the financial aspect of it.”

Le plans to accomplish this task by developing a method to attack and kill the viral DNA that’s associated with chronic hepatitis B infections. She will infect cells and animal models with the virus and then administer the corresponding therapies, making adjustments throughout the experiment when necessary, she explained.

This will be done by combining her prospective vaccine with the current treatment regimes used to manage hepatitis B.

This desire to transfer her research findings from the lab to the patient was incubated during her undergraduate studies at the U of A. As an ambitious student, Le conducted research in Toronto and attended a chemistry conference in Montreal, experiences that solidified both her desire to generate solutions to real-word problems and pursue research with passion and determination.

“I saw that there wasn’t as much translation from research at the bench top to the clinic. Even though there were these amazing discoveries that I could see could very well be used in a clinical setting, for whatever reason they weren’t quite reaching that stage. Then I got interested in how I could bridge that gap,” she said.

Her advice for prospective Vanier Scholars is simple: don’t confine yourself to one commitment, participate in activities you wholeheartedly enjoy and the benefits will come naturally.

“A lot of what the Vanier Scholarship is looking for is not only being good at the research and smart at what you do, but being well-rounded,” she said. “Do things you legitimately enjoy and then things will come from it.”

Ten researchers from the U of A were selected for the 2013 Vanier Canadian Graduate Scholarships.


Submit a comment

By submitting your comment here, you acknowledge that The Gateway reserves the right to publish your comment both online and in print. The Gateway also reserves the right to edit comments for length and clarity when reprinted in the print edition, and to refuse publication (both online and in print) of any comment it deems racist, sexist, libellous or otherwise hateful in nature.

All comments must be approved by a moderator before they will be visible, and may take up to 48 hours to appear. Comments may be no longer than 5000 characters.

Commenting is not available in this channel entry.
Click for details.
daily dose

Faculty of Law proposes tuition increase


Students’ Council — Aug. 19

latest video

Doin’ You: Quick and easy tie dye

The Gateway shows you how to stylishly channel your summer festival attendance into psychedelic print.

latest podcast

Gateway Presents: Moving On

latest blog post

The Vexed Vagina: Transcending tampon territory with the DivaCup


Other than the fact that it hurts and makes me hungry, the biggest thing that bugs me about my period is that it costs a lot of money over time. Not only do I have to endure a week every month of no nice underwear, no sex (but if that’s your thing, all the power to you) and, God forbid, no white pants, I also have to shell out at least $10 every time on bleached cotton. Until a couple months ago.

most popular

#fitspo: How social media shapes fitness culture


The girl in the before and after photo is beautiful — both before and after her drastic 130-pound weight loss.

Fringe show weighs in on fat jokes and discrimination


For more than six million Canadians living with obesity, information about the issue typically comes in the form of lectures, group sessions or dietitian visits. But Dr. Arya Sharma is trying to educate about obesity through an unconventional manner: the Fringe stage.

Letter to the Editor: Don’t turn a blind eye to Hamas terrorism


The Israel-Palestine conflict invokes sharp and passionate responses from everyone—scholars, religious leaders, and politicians and average citizens. Sadly, many in the West choose to be ever so selective in the facts they relay, and the discourse they construct.